Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to explore the efficacy and safety of azacytidine and HAG regimen
versus azacytidine for elderly patients with Newly Diagnosed MDS/AML/CMML in China. This is a
post-marketing, interventional, multi-center, double-arm, prospective, open-label, randomized
controlled study in elderly patients with MDS/AML/CMML in China. Patients will be recruited
consecutively from the study sites during the enrollment period. The enrolled patients will
be given azacytidine + HAG regimen or azacytidine under the conditions of informed consent
and frequent monitoring according to the clinical guideline.